DAVID MOLITERNO, University of Kentucky, Lexington REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials An oral thrombin receptor antagonist, SCH 530348 has proved saf
DAVID MOLITERNO, University of Kentucky, Lexington
REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking TrialsAn oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting byDavid Moliternowho discussed the new data with Peter Goodwin.